Drug Profile
Research programme: small molecule therapeutics - Inventiva Pharma
Alternative Names: EHMT2 inhibitors - Inventiva Pharma; Enhancer of zeste homolog 2 inhibitors - Inventiva Pharma; euchromatic histone-lysine N-methyltransferase 2 - Inventiva Pharma; EZH2 inhibitors - Inventiva Pharma; G9a inhibitors - Inventiva Pharma; histone-lysine N-methyltransferase inhibitors - Inventiva Pharma; NSD2 inhibitors - Inventiva Pharma; TEAD/YAP inhibitors - Inventiva Pharma; YAP/TEAD inhibitors - Inventiva PharmaLatest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Inventiva Pharma
- Developer Curie Institute; Inventiva Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Enhancer of zeste homolog 2 protein inhibitors; Histone-lysine N-methyltransferase inhibitors; Protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Mesothelioma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Respiratory tract disorders; Skin cancer
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Mesothelioma in France (PO)
- 28 Mar 2024 No recent reports of development identified for research development in Breast-cancer in France (PO)
- 28 Mar 2024 No recent reports of development identified for research development in Multiple-myeloma in France (PO)